TRULICITY (dulaglutide) injection

TRULICITY is a brand-name prescription drug that’s FDA-approved to treat type 2 diabetes. TRULICITY (dulaglutide) injection, for subcutaneous use Initial U.S. Approval: 2014

Home | (dulaglutide) injection

TRULICITY (dulaglutide) injection Price In India and Overseas
TRULICITY (dulaglutide) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TRULICITY (dulaglutide) injection

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise.

TRULICITY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated:
• As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Dulaglutide, It is a glucagon-like peptide-1 receptor agonist (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. GLP-1 is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The Food and Drug Administration (FDA) approved dulaglutide for use in the United States in September 2014. It was approved for use in the European Union in November 2014. In 2020, it was the 96th most commonly prescribed medication in the United States, with more than 7 million prescriptions.

Drug (Brand / Generic): TRULICITY / dulaglutide injection
Current Indications: to improve glycemic control, reduce the risk of major adverse cardiovascular events
Marketed by:: t Eli Lilly and Company
Approval Date: 2014

Available as (Form & Strength): • Injection: 0.75 mg/0.5 mL solution in a single-dose pen,
• Injection: 1.5 mg/0.5 mL solution in a single-dose pen,
• Injection: 3 mg/0.5 mL solution in a single-dose pen,
• Injection: 4.5 mg/0.5 mL solution in a single-dose pen.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.